RxDoctor Payments Data

Michelle Kovalaske, MD

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1306023882

Payments from drug & device makers

$19,319in general payments, 2019–2025

Across 55 payments — averaging $351.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • Shire North American Group Inc$3K
  • Novo Nordisk$179
  • Sequel Med Tech, LLC$163
  • Abbott$131
  • BETA Bionics, Inc.$129
  • plus $573 from 11 others

What the payments were for

  • Food & beverage$1,14698%
  • Education$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,319 in reported general payments places this provider in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$63,583
Medicare patients
237
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$244,279
TrulicityDulaglutide74$133,116
MounjaroTirzepatide64$105,365
JardianceEmpagliflozin65$85,378
Teriparatide15$51,485
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$50,589
Humalog Kwikpen U-200Insulin Lispro16$47,054
JanuviaSitagliptin Phosphate35$42,079
FarxigaDapagliflozin Propanediol24$24,836
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$23,600
Tresiba Flextouch U-100Insulin Degludec25$19,412
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$18,065
Lyumjev Kwikpen U-100Insulin Lispro-Aabc11$17,661
Lantus SolostarInsulin Glargine,hum.Rec.Anlog115$16,299
Humalog Kwikpen U-100Insulin Lispro33$15,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$179$244,279130 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$35$242,291149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →